Gene Predictis Overview

  • Year Founded
  • 2004

Year Founded

  • Status
  • Acquired/​Merged

  • Employees
  • 3

Employees

  • Latest Deal Type
  • Buyout/​LBO

  • Financing Rounds
  • 4

Gene Predictis General Information

Description

Developer of polygenic and multifactorial risk scores intended for interpreting complex genetic data. The company develops precision medicines and other diagnostic tools based on genetics that allow tailored treatments to improve drug treatment efficacy and significantly reduce harmful side effects resulting from adverse drug reactions for patients, thus providing physicians with genetic and molecular microbiology analyses for precise clinical results.

Contact Information

Ownership Status
Acquired/Merged
(Operating Subsidiary)
Financing Status
Formerly PE-Backed
Corporate Office
  • EPFL Innovation Park
  • Building B
  • 1015 Lausanne
  • Switzerland
+41 021
Primary Industry
Laboratory Services (Healthcare)
Parent Company
Vertical(s)
Corporate Office
  • EPFL Innovation Park
  • Building B
  • 1015 Lausanne
  • Switzerland
+41 021

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Gene Predictis Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Gene Predictis‘s full profile, request access.

Request a free trial

Gene Predictis Patents

Gene Predictis Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
EP-3333267-A1 Method and kit for predicting the risk of deep vein thrombosis and pulmonary embolism Inactive 09-Dec-2016
WO-2018104545-A1 Method and kit for predicting the risk of deep vein thrombosis and pulmonary embolism Inactive 09-Dec-2016
WO-2018104549-A1 Method for predicting the risk of deep vein thrombosis and pulmonary embolism associated with hormonal preparations and hormone levels Inactive 09-Dec-2016
WO-2018104549-A4 Method for predicting the risk of deep vein thrombosis and pulmonary embolism associated with hormonal preparations and hormone levels Inactive 09-Dec-2016 C12Q1/6883

Gene Predictis Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Gene Predictis Former Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Gene Predictis‘s full profile, request access.

Request a free trial

Gene Predictis FAQs

  • When was Gene Predictis founded?

    Gene Predictis was founded in 2004.

  • Where is Gene Predictis headquartered?

    Gene Predictis is headquartered in Lausanne, Switzerland.

  • What is the size of Gene Predictis?

    Gene Predictis has 3 total employees.

  • What industry is Gene Predictis in?

    Gene Predictis’s primary industry is Laboratory Services (Healthcare).

  • Is Gene Predictis a private or public company?

    Gene Predictis is a Private company.

  • What is Gene Predictis’s current revenue?

    The current revenue for Gene Predictis is .

  • How much funding has Gene Predictis raised over time?

    Gene Predictis has raised $497K.

  • Who are Gene Predictis’s investors?

    EPFL Innovation Park has invested in Gene Predictis.

  • When was Gene Predictis acquired?

    Gene Predictis was acquired on 13-Feb-2023.

  • Who acquired Gene Predictis?

    Gene Predictis was acquired by NIMGenetics.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process